Finance

Lists
IKT:NASDAQ
Inhibikase Therapeutics Inc
US$ १.८९
-१.०५%
(-०.०२०) 1D
अक्टोबर ९, १२:३७:०९ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IKT...
Open
US$ १.९०
High
US$ १.९४
Low
US$ १.८७
Mkt. cap
२६.३७ करोड
Avg. vol.
५.१८ लाख
Volume
१.२७ लाख
52-wk high
US$ २.६१
52-wk low
US$ १.३३
EPS
-US$ ०.४४
Beta
०.८९
Shares outstanding
१३.९५ करोड
No. of employees
३५
Open
US$ १.९०
High
US$ १.९४
Low
US$ १.८७
Mkt. cap
२६.३७ करोड
Avg. vol.
५.१८ लाख
Volume
१.२७ लाख
52-wk high
US$ २.६१
52-wk low
US$ १.३३
EPS
-US$ ०.४४
Beta
०.८९
Shares outstanding
१३.९५ करोड
No. of employees
३५
News stories
From web sources and news partners
Yahoo Finance
Yahoo Finance
·
१ घण्टा पहिले
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
www.marketscreener.com
www.marketscreener.com
·
१३ मिनेट पहिले
TRex Bio Shares Trade Lower in Nasdaq Debut
MarketBeat
MarketBeat
·
२९ मिनेट पहिले
Latigo Biotherapeutics (NASDAQ:LTGO) Shares Climb 6.2% - Time to Buy?
Nasdaq
Nasdaq
·
३ घण्टा पहिले
WISeSat.Space Holdings Corp. Rings the Opening Bell
About Inhibikase Therapeutics Inc
CEO-
Employees३५
Founded२००८
HeadquartersWilmington, डेलावेयर, संयुक्त राज्य अमेरिका
Sector-
Websiteinhibikase.com
Analyst ratings
Based on 5 analysts giving stock ratings to IKT in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for IKT in the last 3 months.
Highest
Current US$ १.८९
US$ ८.०० (+३२३.२८%)
Average
US$ ६.४० (+२३८.६२%)
Lowest
US$ ५.०० (+१६४.५५%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gaurav Maini
LifeSci Capital
Buy
Maintained
US$ ५.००
+१६४.६%
09/15/2026
Jason McCarthy
Maxim Group
Buy
Maintained
US$ ८.००
+३२३.३%
08/13/2026
Mazahir Alimohamed
Oppenheimer
Buy
Maintained
US$ ५.००
+१६४.६%
08/12/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
US$ ८.००
+३२३.३%
07/31/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
US$ ६.००
+२१७.५%
07/27/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Maintained
US$ ४.००
+१११.६%
05/18/2026
Aydin Huseynov
Ladenburg Thalmann & Co.
Buy
Initiated
US$ ४.००
+१११.६%
03/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
७६.५० लाख
-२.३४ करोड
-
-
Cost of revenue
७६.५० लाख
-२.३४ करोड
-
-
Research and development expenses
-
२.२४ करोड
१.०८ करोड
१.३४ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
५६.१२ लाख
६७.७५ लाख
७३.७६ लाख
७६.५८ लाख
Operating expense
५६.१२ लाख
२.९२ करोड
१.८२ करोड
२.११ करोड
Total operating expenses
१.३३ करोड
५७.३३ लाख
१.८२ करोड
२.११ करोड
Operating income
-१.३३ करोड
-५७.३३ लाख
-१.८२ करोड
-२.११ करोड
Other non operating income
-
-
१४.६१ लाख
१४.६० लाख
EBT including unusual items
-१.१९ करोड
-१.२७ करोड
-१.६४ करोड
-१.९६ करोड
EBT excluding unusual items
-१.२४ करोड
-४६.९२ लाख
-१.६८ करोड
-१.९६ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-१.१९ करोड
-१.२७ करोड
-१.६४ करोड
-१.९६ करोड
Net profit margin
-
-
-
-
Earnings per share
-
-
-०.१०
-०.११
Interest and investment income
८.३८ लाख
१०.४१ लाख
-
-
Interest expense
-
-
-
-
Net interest expenses
८.३८ लाख
१०.४१ लाख
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-१.३२ करोड
-५७.३३ लाख
-१.८२ करोड
-२.१० करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू